NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Pemigatinib for treating myeloproliferative neoplasms with an FGFR1 rearrangement ID6172

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
Company	General
Incyte Biosciences UK (pemigatinib)	 All Wales Therapeutics and Toxicology Centre
 Patient/carer groups African Caribbean Leukaemia Trust Anthony Nolan Black Health Agency for Equality Blood Cancer UK Cancer 52 Cancer Black Care Cancer Equality Chronic Myeloid Leukaemia Support Group DKMS Helen Rollason Cancer Charity Independent Cancer Patients Voice Kevin Kararwa Leukaemia Trust Leukaemia Care Lymphoma Action Macmillan Cancer Support 	 Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee
 Maggie's Centres Marie Curie MDS UK Patient Support Group MPN Voice South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care Healthcare professional groups Association of Cancer Physicians British Blood Transfusion Society British Geriatrics Society 	 <u>Possible comparator companies</u> AAH Pharmaceuticals (anagrelide, busulfan, dasatinib, hydroxycarbamide, imatinib, melphalan) Accord-UK Ltd (busulfan, cytarabine, fludarabine, imatinib) Alliance Healthcare (anagrelide, busulfan, cytarabine, hydroxycarbamide, melphalan) Amarox (imatinib) AOP Orphan Pharmaceuticals (ropeginterferon alfa-2b) Aspen Pharma Trading Ltd (busulfan, melphalan)

Provisional stakeholder list for the evaluation of pemigatinib for treating myeloproliferative neoplasms with an FGFR1 rearrangement ID6172 Issue date: January 2024 © National Institute for Health and Care Excellence 2024. All rights reserved.



Consultees	Commentators (no right to submit or appeal)
 British Oncology Pharmacy Association British Psychosocial Oncology Society British Society for Genetic Medicine British Society for Haematology Cancer Research UK NHS Blood and Transplant Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Physicians Royal College of Physicians Royal College of Medicine UK Clinical Pharmacy Association UK Oncology Nursing Society Others Department of Health and Social Care NHS England 	 Aspire (peginterferon alfa-2a) Bristol-Myers Squibb Pharmaceuticals Ltd (dasatinib, fedratinib) Consilient Health Ltd (anagrelide) Dr Reddy's Laboratories UK Ltd (imatinib) Fresenius Kabi Ltd (busulfan) GlaxoSmithKline plc (momelotinib) Glenmark Pharmaceuticals Europe Ltd (anagrelide) Incyte Biosciences UK Ltd (ponatinib) Kent Pharma (UK) Ltd (anagrelide) Masters Pharmaceuticals Ltd (hydroxycarbamide) Medac UK (hydroxycarbamide) Medihealth Northern (anagrelide, hydroxycarbamide) Milpharm Ltd (anagrelide, imatinib) Neon Healthcare (hydroxycarbamide) Nova Laboratories (hydroxycarbamide) Nova Laboratories (hydroxycarbamide) Nova Laboratories (hydroxycarbamide) Novartis Pharmaceuticals UK Ltd (asciminib, imatinib, nilotinib, ruxolitinib) Pfizer (bosutinib, cytarabine, idarubicin) Phoenix Healthcare Distribution Ltd (hydroxycarbamide) Sandoz Ltd (anagrelide, dasatinib, imatinib) Sanofi (fludarabine) Sun Pharmaceuticals (melphalan) Takeda UK Ltd (anagrelide) Teva UK (dasatinib, fludarabine, imatinib) Torrent Pharmaceuticals (anagrelide) Viatris (anagrelide, dasatinib) Zentiva UK (anagrelide, dasatinib, imatinib)

Consultees	Commentators (no right to submit or appeal)
	 Leukaemia Busters Leukaemia UK MRC Clinical Trials Unit National Institute for Health Research
	 <u>Associated Public Health groups</u> Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.